P210
ApoB-100 peptide 210 vaccine antigen — atherosclerosis immunology; ≠ BCR-ABL p210 leukemia fusion.
Editorial review:Evidence snapshot
This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.
Identity lock. P210 in this drawer means the apolipoprotein B-100 peptide epitope centered on apoB residues around 210 (commonly discussed as apoB-100 p210 / peptide 210), studied as an atherosclerosis immunology / vaccine antigen — not BCR-ABL p210 leukemia fusion protein (different “P210” in oncology). No single small-molecule PubChem CID is locked for the antigenic peptide vaccine constructs (fusion proteins, nanoparticles, and carrier formats vary). This drawer marks papers. It is not use advice.
Bottom line
Evidence is preclinical atherosclerosis immunization (mice) plus human observational autoantibody-association studies. Nanoparticle- and antibody-mediated atheroprotection signals appear in apoE−/− and related models. No approved human P210 peptide vaccine is assumed in this pack. Do not confuse with BCR-ABL p210.
Papers
Immunization / vaccine constructs (preclinical)
PMID 35536648 — Chyu 2022
Tested: immunization using ApoB-100 peptide-linked nanoparticles reduces atherosclerosis (preclinical).
Does not show: an approved human atherosclerosis vaccine.
PMID 33907226 — Dunér 2021
Tested: antibodies against apoB100 peptide 210 inhibit atherosclerosis in apoE−/− mice.
Does not show: human clinical vaccine efficacy.
PMID 32970979 — Yi 2020
Tested: retinoic-acid-loaded PLGA nanoparticle formulation of ApoB-100-derived peptide 210 attenuates atherosclerosis (preclinical).
Does not show: human outcome data.
PMID 25677313 — Honjo 2015
Tested: ApoB-100-related peptide vaccine protects against angiotensin II-induced aortic aneurysm formation and rupture (mice).
Does not show: human aneurysm prevention trial.
PMID 26121471 — Honjo 2015
Tested: immunization with an ApoB-100 related peptide vaccine attenuates Ang-II hypertension and renal fibrosis in mice.
Does not show: human hypertension vaccine approval.
PMID 30018722 — Zeng 2018
Tested: apoB-100 peptide 210 antibody inhibits atherosclerosis via macrophage regulation in models.
Does not show: a completed human Phase 3 vaccine package.
PMID 30243560 — Rattik 2018
Tested: B cells treated with CTB-p210 acquire a regulatory phenotype in vitro and reduce atherosclerosis in apoE-deficient mice (p210-linked construct).
Does not show: human clinical efficacy.
Human association / autoantibody context
PMID 24401246 — McLeod 2014
Tested: plasma autoantibodies against apoB-100 peptide 210 in subclinical atherosclerosis (human observational).
Does not show: that measuring or “boosting” p210 immunity is an approved therapy.
PMID 19448981 — Fredrikson 2009
Tested: associations between autoantibodies against apoB-100 peptides and vascular complications in type 2 diabetes (observational).
Does not show: interventional vaccine proof.
PMID 20167655 — Klingenberg 2010
Tested: intranasal immunization with an apoB-100 fusion protein induces antigen-specific Treg and reduces atherosclerosis (preclinical; related apoB vaccine lineage).
Does not show: human intranasal P210 product approval.
What is not established
Approved human P210 peptide vaccine for atherosclerosis. Equivalence of every “P210” shop label to a characterized apoB-100 p210 antigen. Any identity with BCR-ABL p210 leukemia fusion. This drawer does not provide use advice, schedules, or sourcing.
Selected sources
35536648 33907226 32970979 25677313 26121471 30018722 30243560 24401246 19448981 20167655
Reported experiences
Reported topics are not established benefits.Risks and unknowns
Compare experiences with care.
Join the discussion
Verified members can contribute to compound conversations.